BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, Airoldi A, Giacomoni A, Rondinara G, Tinelli C. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100:2708-2716. [PMID: 16393224 DOI: 10.1111/j.1572-0241.2005.00289.x] [Cited by in Crossref: 176] [Cited by in F6Publishing: 162] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Takahashi S, Kudo M, Chung H, Inoue T, Nagashima M, Kitai S, Tatsumi C, Minami Y, Ueshima K, Fukunaga T. Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation. Dig Dis. 2007;25:303-309. [PMID: 17960064 DOI: 10.1159/000106909] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
2 Jakate S, Yabes A, Giusto D, Naini B, Lassman C, Yeh MM, Ferrell LD. Diffuse cirrhosis-like hepatocellular carcinoma: a clinically and radiographically undetected variant mimicking cirrhosis. Am J Surg Pathol. 2010;34:935-941. [PMID: 20463569 DOI: 10.1097/pas.0b013e3181ddf52f] [Cited by in Crossref: 34] [Cited by in F6Publishing: 9] [Article Influence: 3.1] [Reference Citation Analysis]
3 Yang LS, Shan LL, Saxena A, Morris DL. Liver transplantation: a systematic review of long-term quality of life. Liver Int. 2014;34:1298-1313. [PMID: 24703371 DOI: 10.1111/liv.12553] [Cited by in Crossref: 79] [Cited by in F6Publishing: 56] [Article Influence: 11.3] [Reference Citation Analysis]
4 Civan JM. Liver Transplantation for HCC: The Milan Criteria. In: Doria C, editor. Contemporary Liver Transplantation. Cham: Springer International Publishing; 2016. pp. 1-19. [DOI: 10.1007/978-3-319-05543-5_11-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, Suh KS, Weber A, Burroughs AK. Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl. 2011;17 Suppl 2:S58-S66. [PMID: 21584928 DOI: 10.1002/lt.22336] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
6 Shin SK, Kim YS, Shim YS, Choi SJ, Park SH, Jung DH, Kwon OS, Choi DJ, Kim JH. Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma: A STROBE-compliant article. Medicine (Baltimore) 2017;96:e7761. [PMID: 28816953 DOI: 10.1097/MD.0000000000007761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
7 Oligane HC, Xing M, Kim HS. Effect of Bridging Local-Regional Therapy on Recurrence of Hepatocellular Carcinoma and Survival after Orthotopic Liver Transplantation. Radiology 2017;282:869-79. [DOI: 10.1148/radiol.2016160288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
8 Sun L, Wu H, Guan YS. Positron emission tomography/computer tomography: challenge to conventional imaging modalities in evaluating primary and metastatic liver malignancies. World J Gastroenterol 2007;13:2775-83. [PMID: 17569111 DOI: 10.3748/wjg.v13.i20.2775] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
9 Sotiropoulos GC, Beckebaum S, Lang H, Frilling A, Molmenti EP, Cicinnati VR, Saner FH, Erim Y, Baba HA, Malagó M. Single-center experience on liver transplantation for hepatocellular carcinoma arising in alcoholic cirrhosis: results and ethical issues. Eur Surg Res. 2008;40:7-13. [PMID: 17717419 DOI: 10.1159/000107615] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
10 Löhe F, Angele MK, Rentsch M, Graeb C, Gerbes A, Löhrs U, Beuers U, Jauch KW. Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation. Clin Transplant 2007;21:696-701. [PMID: 17988261 DOI: 10.1111/j.1399-0012.2007.00707.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
11 Wang Y, Liao J, Qi W, Xie L, Li Y. Predictive Value of Conventional Ultrasound and Contrast-Enhanced Ultrasound in Early Recurrence of Hepatocellular Carcinoma after Surgical Resection. Ultrasound Med Biol. 2016;42:1042-1048. [PMID: 26803390 DOI: 10.1016/j.ultrasmedbio.2015.12.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hollebecque A, Decaens T, Boleslawski E, Mathurin P, Duvoux C, Pruvot FR, Dharancy S. Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol. 2009;33:361-369. [PMID: 19398289 DOI: 10.1016/j.gcb.2009.02.036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
13 Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl. 2008;14:935-945. [PMID: 18581465 DOI: 10.1002/lt.21445] [Cited by in Crossref: 206] [Cited by in F6Publishing: 189] [Article Influence: 15.8] [Reference Citation Analysis]
14 Kornberg A, Freesmeyer M, Bärthel E, Jandt K, Katenkamp K, Steenbeck J, Sappler A, Habrecht O, Gottschild D, Settmacher U. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant. 2009;9:592-600. [PMID: 19191771 DOI: 10.1111/j.1600-6143.2008.02516.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 112] [Article Influence: 9.7] [Reference Citation Analysis]
15 Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009;29:74-81. [PMID: 18331238 DOI: 10.1111/j.1478-3231.2008.01702.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
16 Marelli L, Grasso A, Pleguezuelo M, Martines H, Stigliano R, Dhillon AP, Patch D, Davidson BR, Sharma D, Rolles K, Burroughs AK. Tumour size and differentiation in predicting recurrence of hepatocellular carcinoma after liver transplantation: external validation of a new prognostic score. Ann Surg Oncol. 2008;15:3503-3511. [PMID: 18777193 DOI: 10.1245/s10434-008-0128-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
17 Yoon YC, Hong TH, You YK, Kim DG. Clinical analysis of recurrent hepatocellular carcinoma after living donor liver transplantation. Clin Transplant. 2013;27:E192-E198. [PMID: 23383956 DOI: 10.1111/ctr.12090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
19 Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, De Simone P, Filipponi F, Bartolozzi C. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation. Radiology. 2010;255:289-300. [PMID: 20308465 DOI: 10.1148/radiol.09090927] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 4.7] [Reference Citation Analysis]
20 Mourad W, Khalaf H, Tulbah A, Al Omari M, Al Mana H, Neimatallah M. Clinicopathologic features of hepatic neoplasms in explanted livers: a single institution experience. Ann Saudi Med 2007;27:437-41. [PMID: 18059117 DOI: 10.5144/0256-4947.2007.437] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
21 Kakihara D, Nishie A, Harada N, Shirabe K, Tajima T, Asayama Y, Ishigami K, Nakayama T, Takayama Y, Okamoto D, Fujita N, Kishimoto J, Honda H. Performance of gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in recipients of living-related-liver-transplantation: comparison with dynamic multidetector row computed tomography and angiography-assisted computed tomography. J Magn Reson Imaging 2014;40:1112-20. [PMID: 24259437 DOI: 10.1002/jmri.24454] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
22 Abou-alfa GK, Jarnagin W, El Dika I, D'angelica M, Lowery M, Brown K, Ludwig E, Kemeny N, Covey A, Crane CH, Harding J, Shia J, O'reilly EM. Liver and Bile Duct Cancer. Abeloff's Clinical Oncology. Elsevier; 2020. pp. 1314-1341.e11. [DOI: 10.1016/b978-0-323-47674-4.00077-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Fortune BE, Umman V, Gilliland T, Emre S. Liver transplantation for hepatocellular carcinoma: a surgical perspective. J Clin Gastroenterol 2013;47 Suppl:S37-42. [PMID: 23632344 DOI: 10.1097/MCG.0b013e318286ff8e] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
24 Ataide EC, Perales SR, Silva MG, Filho FC, Sparapani AC, Latuf Filho PF, Stucchi RSB, Vassallo J, Escanhoela CAF, Boin IFSF. Immunoexpression of Heat Shock Protein 70, Glypican 3, Glutamine Synthetase, and Beta-Catenin in Hepatocellular Carcinoma After Liver Transplantation: Association Between Positive Glypican 3 and Beta-Catenin With the Presence of Larger Nodules. Transplant Proc. 2017;49:858-862. [PMID: 28457411 DOI: 10.1016/j.transproceed.2017.01.048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
25 Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Yamashita Y, Maehara Y. Liver transplantation for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2008;15:124-30. [DOI: 10.1007/s00534-007-1296-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
26 Kim SH, Moon DB, Kim WJ, Kang WH, Kwon JH, Jwa EK, Cho HD, Ha SM, Chung YK, Lee SG. Preoperative prognostic values of α-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) in patients with hepatocellular carcinoma for living donor liver transplantation. Hepatobiliary Surg Nutr 2016;5:461-9. [PMID: 28124000 DOI: 10.21037/hbsn.2016.11.05] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
27 Emmanouilidis N, Peters R, Ringe BP, Güner Z, Ramackers W, Bektas H, Lehner F, Manns M, Klempnauer J, Schrem H. Liver Transplantation for Hepatocellular Carcinoma: A Single Center Resume Overlooking Four Decades of Experience. J Transplant 2016;2016:7895956. [PMID: 27057348 DOI: 10.1155/2016/7895956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
28 Hakeem AR, Young RS, Marangoni G, Lodge JP, Prasad KR. Systematic review: the prognostic role of alpha-fetoprotein following liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:987-999. [PMID: 22429190 DOI: 10.1111/j.1365-2036.2012.05060.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 1.9] [Reference Citation Analysis]
29 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 114] [Article Influence: 10.7] [Reference Citation Analysis]
30 Yaprak O, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y, Tokat Y. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2012;11:256-61. [PMID: 22672818 DOI: 10.1016/s1499-3872(12)60157-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
31 Pommergaard HC, Burcharth J, Rosenberg J, Rasmussen A. Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2016;30:171-177. [PMID: 27118303 DOI: 10.1016/j.trre.2016.03.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
32 Freeman RB. Transplantation for hepatocellular carcinoma: The Milan criteria and beyond. Liver Transpl. 2006;12:S8-13. [PMID: 17051567 DOI: 10.1002/lt.20936] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
33 Macaron C, Hanouneh IA, Lopez R, Aucejo F, Zein NN. Total tumor volume predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria. Transplant Proc. 2010;42:4585-4592. [PMID: 21168743 DOI: 10.1016/j.transproceed.2010.10.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
34 Zhang H, Yuan SX, Dai SY, Zhang JM, Huang X, Lu CD, Lu JH, Wu FQ, Lau WY, Wu MC, Yang T, Shen F. Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg 2014;38:947-57. [PMID: 24258262 DOI: 10.1007/s00268-013-2365-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
35 Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, Chiou YY, Chiang JH, Lee PC, Huo TI. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol. 2010;53:108-117. [PMID: 20451283 DOI: 10.1016/j.jhep.2010.01.038] [Cited by in Crossref: 106] [Cited by in F6Publishing: 99] [Article Influence: 9.6] [Reference Citation Analysis]
36 Chan SC, Fan ST, Chok KS, Cheung TT, Chan AC, Fung JY, Poon RT, Lo CM. Survival advantage of primary liver transplantation for hepatocellular carcinoma within the up-to-7 criteria with microvascular invasion. Hepatol Int. 2012;6:646-656. [PMID: 22016140 DOI: 10.1007/s12072-011-9318-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
37 Kohli V, Singhal A, Elliott L, Jalil S. Antiviral therapy for recurrent hepatitis C reduces recurrence of hepatocellular carcinoma following liver transplantation. Transpl Int. 2012;25:192-200. [PMID: 22151471 DOI: 10.1111/j.1432-2277.2011.01396.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
38 Varona MA, Del Pino JM, Barrera M, Arranz J, Hernández BM, Perez HF, Padilla J, Fuentes JS, Aguirre A, Mendez S. Hepatocellular carcinoma and liver transplantation: a 12-year experience. Transplant Proc. 2009;41:1005-1008. [PMID: 19376411 DOI: 10.1016/j.transproceed.2009.02.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
39 Jiang G, Ling S, Zhan Q, Zhuang L, Xu X. Downstaging treatment for patients with hepatocelluar carcinoma before transplantation. Transplant Rev (Orlando) 2021;35:100606. [PMID: 33636480 DOI: 10.1016/j.trre.2021.100606] [Reference Citation Analysis]
40 Shafizadeh N, Kakar S. Hepatocellular Carcinoma: Histologic Subtypes. Surg Pathol Clin. 2013;6:367-384. [PMID: 26838979 DOI: 10.1016/j.path.2013.03.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
41 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
42 Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R, Cameron A, Ghobrial M, Kam I, Busuttil R. Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues. Liver Transpl. 2013;19:1020-1029. [PMID: 23852663 DOI: 10.1002/lt.23703] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
43 Cescon M, Ravaioli M, Grazi GL, Ercolani G, Cucchetti A, Bertuzzo V, Vetrone G, Del Gaudio M, Vivarelli M, D'Errico-Grigioni A, Dazzi A, Di Gioia P, Lauro A, Pinna AD. Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant 2010;2010:904152. [PMID: 20862199 DOI: 10.1155/2010/904152] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
44 Chang ML, Lin SM, Yeh CT. HURP expression-assisted risk scores identify prognosis distinguishable subgroups in early stage liver cancer. PLoS One 2011;6:e26323. [PMID: 22022601 DOI: 10.1371/journal.pone.0026323] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
45 Schwartz M, D'amico F, Vitale A, Emre S, Cillo U. Liver transplantation for hepatocellular carcinoma: Are the Milan criteria still valid? European Journal of Surgical Oncology (EJSO) 2008;34:256-62. [DOI: 10.1016/j.ejso.2007.07.208] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
46 Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, Joh JW, Lee SK. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis. 2007;25:313-319. [PMID: 17960066 DOI: 10.1159/000106911] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
47 Sawada T, Kubota K. Liver transplantation for hepatocellular carcinoma. Dig Surg 2007;24:126-30. [PMID: 17446707 DOI: 10.1159/000101900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
48 Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17 Suppl 2:S44-S57. [PMID: 21695773 DOI: 10.1002/lt.22365] [Cited by in Crossref: 320] [Cited by in F6Publishing: 286] [Article Influence: 35.6] [Reference Citation Analysis]
49 Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer. 2015;15:465. [PMID: 26059447 DOI: 10.1186/s12885-015-1480-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
50 Lee SD, Kim SH, Kim YK, Kim C, Kim SK, Han SS, Park SJ. (18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma. Transpl Int. 2013;26:50-60. [PMID: 23106431 DOI: 10.1111/j.1432-2277.2012.01572.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
51 Chan EY, Larson AM, Fix OK, Yeh MM, Levy AE, Bakthavatsalam R, Halldorson JB, Reyes JD, Perkins JD. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl. 2008;14:956-965. [PMID: 18581511 DOI: 10.1002/lt.21449] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
52 Zendejas-ruiz I, Hemming AW, Chen C, Schwartz JJ, Sorensen JB, Kim RD. Recurrent Hepatocellular Carcinoma in Liver Transplant Recipients with Hepatitis C. J Gastrointest Canc 2012;43:229-35. [DOI: 10.1007/s12029-010-9230-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
53 Marshall AE, Rushbrook SM, Vowler SL, Palmer CR, Davies RJ, Gibbs P, Davies SE, Coleman N, Alexander GJ. Tumor recurrence following liver transplantation for hepatocellular carcinoma: role of tumor proliferation status. Liver Transpl. 2010;16:279-288. [PMID: 20209638 DOI: 10.1002/lt.21993] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
54 Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AM, Kneteman NM. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 2008;14:1107-1115. [PMID: 18668667 DOI: 10.1002/lt.21484] [Cited by in Crossref: 157] [Cited by in F6Publishing: 154] [Article Influence: 12.1] [Reference Citation Analysis]
55 Guiteau JJ, Cotton RT, Washburn WK, Harper A, O’Mahony CA, Sebastian A, Cheng S, Klintmalm G, Ghobrial M, Halff G. An early regional experience with expansion of Milan Criteria for liver transplant recipients. Am J Transplant. 2010;10:2092-2098. [PMID: 20883543 DOI: 10.1111/j.1600-6143.2010.03222.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
56 Koschny R, Schmidt J, Ganten TM. Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis. Clin Transplant 2009;23 Suppl 21:49-60. [PMID: 19930317 DOI: 10.1111/j.1399-0012.2009.01110.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
57 Feng Y, Qin X, Luo Y, Li Y, Zhou X. Efficacy of Contrast-Enhanced Ultrasound Washout Rate in Predicting Hepatocellular Carcinoma Differentiation. Ultrasound in Medicine & Biology 2015;41:1553-60. [DOI: 10.1016/j.ultrasmedbio.2015.01.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
58 Heimbach JK. Liver transplantation for hepatocellular carcinoma. Cancer J 2008;14:95-9. [PMID: 18391614 DOI: 10.1097/PPO.0b013e31816a0f6f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
59 Farris AB, Dursun N, Dhanasekaran R, Coban I, McIntosh EB, Adsay NV, Kim HS. Tumoral and angiogenesis factors in hepatocellular carcinoma after locoregional therapy. Pathol Res Pract. 2012;208:15-21. [PMID: 22088254 DOI: 10.1016/j.prp.2011.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
60 Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, Lurje G. Treatment Strategies for Hepatocellular Carcinoma ⁻ a Multidisciplinary Approach. Int J Mol Sci 2019;20:E1465. [PMID: 30909504 DOI: 10.3390/ijms20061465] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 22.5] [Reference Citation Analysis]
61 Kim DY, Kim JW, Kuromatsu R, Ahn SH, Torimura T, Sherman M. Controversies in surveillance and early diagnosis of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:56-60. [PMID: 22212937 DOI: 10.1159/000333261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
62 Aziz S, Sey M, Marotta P, Driman D, Parfitt J, Teriaky A, Brahmania M, Skaro A, Qumosani K. Recurrent Hepatocellular Carcinoma After Liver Transplantation: Validation of a Pathologic Risk Score on Explanted Livers to Predict Recurrence. Transplant Proc 2021;53:1975-9. [PMID: 34272052 DOI: 10.1016/j.transproceed.2021.05.007] [Reference Citation Analysis]
63 Chang WC, Chen RC, Chou CT, Lin CY, Yu CY, Liu CH, Chou JM, Hsu HH, Huang GS. Histological grade of hepatocellular carcinoma correlates with arterial enhancement on gadoxetic acid-enhanced and diffusion-weighted MR images. Abdom Imaging 2014;39:1202-12. [PMID: 24869790 DOI: 10.1007/s00261-014-0168-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
64 Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis. 2007;25:329-333. [PMID: 17960068 DOI: 10.1159/000106913] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
65 Ioannou GN, Perkins JD, Carithers RL. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134:1342-1351. [PMID: 18471511 DOI: 10.1053/j.gastro.2008.02.013] [Cited by in Crossref: 193] [Cited by in F6Publishing: 176] [Article Influence: 14.8] [Reference Citation Analysis]
66 Pagano D, Barbera F, Conaldi PG, Seidita A, Di Francesco F, Di Carlo D, Bàrbara M, Tuzzolino F, Luca A, Gruttadauria S. Role of Allelic Imbalance in Predicting Hepatocellular Carcinoma (HCC) Recurrence Risk After Liver Transplant. Ann Transplant 2019;24:223-33. [PMID: 31015392 DOI: 10.12659/AOT.913692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
67 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3.] [Reference Citation Analysis]
68 Donat M, Alonso S, Pereira F, Ferrero E, Carrión L, Acin-Gándara D, Moreno E. Impact of Histological Factors of Hepatocellular Carcinoma on the Outcome of Liver Transplantation. Transplant Proc 2016;48:1968-77. [PMID: 27569930 DOI: 10.1016/j.transproceed.2016.04.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
69 Vitale A, Gringeri E, Valmasoni M, D'Amico F, Carraro A, Pauletto A, D'Amico FJ, Polacco M, D'Amico DF, Cillo U. Long-term results of liver transplantation for hepatocellular carcinoma: an update of the University of Padova experience. Transplant Proc 2007;39:1892-4. [PMID: 17692645 DOI: 10.1016/j.transproceed.2007.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
70 Zhang R, Guo H, Xu J, Li B, Liu YJ, Cheng C, Zhou C, Zhao Y, Liu Y. Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding. Oncotarget 2016;7:60609-22. [PMID: 27542264 DOI: 10.18632/oncotarget.11300] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
71 Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909-922. [PMID: 17522517 DOI: 10.1097/01.sla.0000254368.65878.da] [Cited by in Crossref: 220] [Cited by in F6Publishing: 212] [Article Influence: 15.7] [Reference Citation Analysis]
72 Hirokawa F, Kubo S, Nagano H, Nakai T, Kaibori M, Hayashi M, Takemura S, Wada H, Nakata Y, Matsui K, Ishizaki M, Uchiyama K. Do patients with small solitary hepatocellular carcinomas without macroscopically vascular invasion require anatomic resection? Propensity score analysis. Surgery 2015;157:27-36. [DOI: 10.1016/j.surg.2014.06.080] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
73 Dudek K, Kornasiewicz O, Remiszewski P, Kobryń K, Ziarkiewicz-Wróblewska B, Górnicka B, Zieniewicz K, Krawczyk M. Impact of tumor characteristic on the outcome of liver transplantation in patients with hepatocellular carcinoma. Transplant Proc 2009;41:3135-7. [PMID: 19857695 DOI: 10.1016/j.transproceed.2009.08.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
74 Thuluvath PJ. Vascular invasion is the most important predictor of survival in HCC, but how do we find it? J Clin Gastroenterol 2009;43:101-2. [PMID: 19142172 DOI: 10.1097/MCG.0b013e318191e64f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
75 Ataide EC, Boin IF, Almeida JR, Sevá-Pereira T, Stucchi RS, Cardoso AR, Caruy CA, Escanhoela CA. Prognostic factors for hepatocellular carcinoma recurrence: experience with 83 liver transplantation patients. Transplant Proc 2011;43:1362-4. [PMID: 21620130 DOI: 10.1016/j.transproceed.2011.02.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
76 De Carlis L, Di Sandro S, Giacomoni A, Slim A, Lauterio A, Mangoni I, Mihaylov P, Pirotta V, Aseni P, Rampoldi A. Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation? J Clin Gastroenterol. 2012;46:78-86. [PMID: 21897282 DOI: 10.1097/mcg.0b013e31822b36f6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
77 Ma E, Li J, Xing H, Li R, Shen C, Zhang Q, Ma Z, Tao Y, Qin L, Zhao J, Wang Z. Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation. Ann Transl Med 2021;9:468. [PMID: 33850865 DOI: 10.21037/atm-21-334] [Reference Citation Analysis]
78 Maruyama H, Takahashi M, Sekimoto T, Kamesaki H, Shimada T, Kanai F, Yokosuka O. Heterogeneity of microbubble accumulation: a novel approach to discriminate between well-differentiated hepatocellular carcinomas and regenerative nodules. Ultrasound Med Biol 2012;38:383-8. [PMID: 22261511 DOI: 10.1016/j.ultrasmedbio.2011.12.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
79 Morris-stiff G, Gomez D, de Liguori Carino N, Prasad K. Surgical management of hepatocellular carcinoma: Is the jury still out? Surgical Oncology 2009;18:298-321. [DOI: 10.1016/j.suronc.2008.08.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
80 Moghe A, Ganesh S, Humar A, Molinari M, Jonassaint N. Expanding Donor Selection and Recipient Indications for Living Donor Liver Transplantation. Clin Liver Dis 2021;25:121-35. [PMID: 33978574 DOI: 10.1016/j.cld.2020.08.011] [Reference Citation Analysis]
81 Vibert E, Samuel D. Molecular tools and hepatocellular carcinoma: Adding help or confusion in liver transplantation? Journal of Hepatology 2008;49:498-501. [DOI: 10.1016/j.jhep.2008.07.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
82 Takahashi M, Maruyama H, Ishibashi H, Yoshikawa M, Yokosuka O. Contrast-Enhanced Ultrasound With Perflubutane Microbubble Agent: Evaluation of Differentiation of Hepatocellular Carcinoma. American Journal of Roentgenology 2011;196:W123-31. [DOI: 10.2214/ajr.10.4242] [Cited by in Crossref: 35] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
83 Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World J Gastroenterol. 2018;24:5081-5094. [PMID: 30568386 DOI: 10.3748/wjg.v24.i45.5081] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
84 Wang YL, Zhu ZJ, Teng DH, Yao Z, Gao W, Shen ZY. Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation. World J Gastroenterol. 2012;18:2408-2414. [PMID: 22654434 DOI: 10.3748/wjg.v18.i19.2408] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
85 Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531-537. [PMID: 19307789 DOI: 10.1097/tp.0b013e3181943bee] [Cited by in Crossref: 113] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
86 López Ortega S, González Grande R, Santaella Leiva I, De la Cruz Lombardo J, Jiménez Pérez M. Efficacy and Safety of Sorafenib After Liver Transplantation: Experience in Our Center. Transplant Proc 2020;52:540-2. [PMID: 32057495 DOI: 10.1016/j.transproceed.2019.12.016] [Reference Citation Analysis]
87 Zheng YW, Nie YZ, Taniguchi H. Cellular reprogramming and hepatocellular carcinoma development. World J Gastroenterol. 2013;19:8850-8860. [PMID: 24379607 DOI: 10.3748/wjg.v19.i47.8850] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
88 Han ZB, Zhong L, Teng MJ, Fan JW, Tang HM, Wu JY, Chen HY, Wang ZW, Qiu GQ, Peng ZH. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation. Mol Oncol. 2012;6:445-457. [PMID: 22552153 DOI: 10.1016/j.molonc.2012.04.001] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 7.7] [Reference Citation Analysis]
89 Lee JW, Paeng JC, Kang KW, Kwon HW, Suh K, Chung J, Lee MC, Lee DS. Prediction of Tumor Recurrence by 18 F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma. J Nucl Med 2009;50:682-7. [DOI: 10.2967/jnumed.108.060574] [Cited by in Crossref: 118] [Cited by in F6Publishing: 104] [Article Influence: 9.8] [Reference Citation Analysis]
90 Duvoux C. Transplantation hépatique pour carcinome hépatocellulaire. Gastroentérologie Clinique et Biologique 2006;30:1343-5. [DOI: 10.1016/s0399-8320(06)73551-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
91 Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation. 2007;83:1162-1168. [PMID: 17496530 DOI: 10.1097/01.tp.0000262607.95372.e0] [Cited by in Crossref: 137] [Cited by in F6Publishing: 115] [Article Influence: 9.8] [Reference Citation Analysis]
92 Salgia RJ, Goodrich NP, Marrero JA, Volk ML. Donor Factors Similarly Impact Survival Outcome After Liver Transplantation in Hepatocellular Carcinoma and Non-hepatocellular Carcinoma Patients. Dig Dis Sci 2014;59:214-9. [DOI: 10.1007/s10620-013-2883-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
93 Romano F, Stroppa P, Bravi M, Casotti V, Lucianetti A, Guizzetti M, Sonzogni A, Colledan M, D’Antiga L. Favorable outcome of primary liver transplantation in children with cirrhosis and hepatocellular carcinoma. Pediatr Transplant. 2011;15:573-579. [PMID: 21797955 DOI: 10.1111/j.1399-3046.2011.01528.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
94 Schwartz JJ, Pappas L, Thiesset HF, Vargas G, Sorensen JB, Kim RD, Hutson WR, Boucher K, Box T. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience. Liver Transpl. 2012;18:423-433. [PMID: 22250078 DOI: 10.1002/lt.23385] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
95 Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol. 2012;138:153-161. [PMID: 22071603 DOI: 10.1007/s00432-011-1076-z] [Cited by in Crossref: 78] [Cited by in F6Publishing: 84] [Article Influence: 7.8] [Reference Citation Analysis]
96 Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant. 2009;9:2362-2371. [PMID: 19656125 DOI: 10.1111/j.1600-6143.2009.02783.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 8.6] [Reference Citation Analysis]
97 Jha RC, Zanello PA, Nguyen XM, Pehlivanova M, Johnson LB, Fishbein T, Shetty K. Small hepatocellular carcinoma: MRI findings for predicting tumor growth rates. Acad Radiol. 2014;21:1455-1464. [PMID: 25300723 DOI: 10.1016/j.acra.2014.06.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
98 Sakaguchi T, Suzuki S, Morita Y, Oishi K, Suzuki A, Fukumoto K, Inaba K, Nakamura S, Konno H. Impact of the preoperative des-gamma-carboxy prothrombin level on prognosis after hepatectomy for hepatocellular carcinoma meeting the Milan criteria. Surg Today. 2010;40:638-645. [PMID: 20582515 DOI: 10.1007/s00595-009-4109-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
99 Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, Steinberg T, Bennett W, Kam I. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transplant Int 2007;20:747-53. [DOI: 10.1111/j.1432-2277.2007.00505.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
100 Oishi K, Itamoto T, Amano H, Fukuda S, Ohdan H, Tashiro H, Shimamoto F, Asahara T. Clinicopathologic features of poorly differentiated hepatocellular carcinoma. J Surg Oncol. 2007;95:311-316. [PMID: 17326126 DOI: 10.1002/jso.20661] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
101 Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS, Cameron A, Ghobrial M, Kam I, Busuttil R. Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Clin Transplant. 2013;27:829-837. [PMID: 24033475 DOI: 10.1111/ctr.12224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
102 Díaz-Sánchez A, Matilla A, Núñez O, Merino B, Peligros I, Rincón D, Salcedo M, Lo Iacono O, Vega Catalina M, Clemente G, Bañares R. [Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival]. Gastroenterol Hepatol 2010;33:155-64. [PMID: 19945770 DOI: 10.1016/j.gastrohep.2009.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
103 Chen J, Xu X, Ling Q, Wu J, Zheng S. Role of Pittsburgh Modified TNM Criteria in prognosis prediction of liver transplantation for hepatocellular carcinoma: . Chinese Medical Journal 2007;120:2200-3. [DOI: 10.1097/00029330-200712020-00008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
104 Yuan ZG, Wang ZY, Xia MY, Li FZ, Li Y, Shen Z, Wang XZ. Diffusion Kurtosis Imaging for Assessing the Therapeutic Response of Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma. J Cancer 2020;11:2339-47. [PMID: 32127960 DOI: 10.7150/jca.32491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 de la Fuente S, Citores MJ, Lucena JL, Muñoz P, Cuervas-Mons V. TLR9-1486C/T polymorphism is associated with hepatocellular carcinoma recurrence after liver transplantation. Biomark Med 2019;13:995-1004. [PMID: 31317790 DOI: 10.2217/bmm-2019-0030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
106 Fu SJ, Ji F, Han M, Chen MG, Wang XP, Ju WQ, Zhao Q, Wu LW, Ren QQ, Guo ZY, Wang DP, Zhu XF, Ma Y, He XS. Prognostic value of combined preoperative fibrinogen and neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma after liver transplantation. Oncotarget. 2017;8:4301-4312. [PMID: 27935864 DOI: 10.18632/oncotarget.13804] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
107 Stravitz RT, Heuman DM, Chand N, Sterling RK, Shiffman ML, Luketic VA, Sanyal AJ, Habib A, Mihas AA, Giles HC, Maluf DG, Cotterell AH, Posner MP, Fisher RA. Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med. 2008;121:119-126. [PMID: 18261500 DOI: 10.1016/j.amjmed.2007.09.020] [Cited by in Crossref: 104] [Cited by in F6Publishing: 94] [Article Influence: 8.0] [Reference Citation Analysis]
108 Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012;82:116-40. [DOI: 10.1016/j.critrevonc.2011.05.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
109 Deshpande R, O'Reilly D, Sherlock D. Improving Outcomes with Surgical Resection and Other Ablative Therapies in HCC. Int J Hepatol 2011;2011:686074. [PMID: 21994867 DOI: 10.4061/2011/686074] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
110 Yang Z, Zhou L, Wu LM, Xie HY, Zhang F, Zheng SS. Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy. Clin Chem Lab Med. 2010;48:1785-1791. [PMID: 20731616 DOI: 10.1515/CCLM.2010.353] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
111 Jin YJ, Cho SG, Lee KY, Kim JM, Lee JW. Association between relative liver enhancement on gadoxetic acid enhanced magnetic resonance images and histologic grade of hepatocellular carcinoma. Medicine (Baltimore) 2017;96:e7580. [PMID: 28746206 DOI: 10.1097/MD.0000000000007580] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
112 Yokoyama K, Anan A, Iwata K, Nishizawa S, Morihara D, Ueda S, Sakurai K, Iwashita H, Hirano G, Sakamoto M. Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: proposal of a three (times) × 3 (years) index. J Gastroenterol Hepatol. 2012;27:1044-1050. [PMID: 22433056 DOI: 10.1111/j.1440-1746.2012.07134.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
113 Shaaban A, Salamah R, Abo Elseud Y, Mohanty A, Albarrak J. Presentation and Outcomes of Hepatocellular Carcinoma in the Arabian Peninsula: A Review of a Single Institution Experience in the Sorafenib Era. J Gastrointest Cancer 2021;52:85-9. [PMID: 31808059 DOI: 10.1007/s12029-019-00341-7] [Reference Citation Analysis]
114 Maheswaran T, Rushbrook SM. Epithelial-mesenchymal transition and the liver: role in hepatocellular carcinoma and liver fibrosis. J Gastroenterol Hepatol. 2012;27:418-420. [PMID: 22353346 DOI: 10.1111/j.1440-1746.2012.07060.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
115 Onaca N, Davis GL, Goldstein RM, Jennings LW, Klintmalm GB. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2007;13:391-399. [PMID: 17318865 DOI: 10.1002/lt.21095] [Cited by in Crossref: 142] [Cited by in F6Publishing: 121] [Article Influence: 10.1] [Reference Citation Analysis]
116 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
117 Moon JI, Kwon CH, Joh JW, Choi GS, Jung GO, Kim JM, Shin M, Choi SJ, Kim SJ, Lee SK. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival. Transplant Proc. 2012;44:487-493. [PMID: 22410053 DOI: 10.1016/j.transproceed.2011.11.009] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
118 Sun H, Tang H, Xie D, Jia Z, Ma Z, Wei D, Mishra L, Gao Y, Zheng S, Xie K, Peng Z. Krüppel-like Factor 4 Blocks Hepatocellular Carcinoma Dedifferentiation and Progression through Activation of Hepatocyte Nuclear Factor-6. Clin Cancer Res 2016;22:502-12. [PMID: 26338995 DOI: 10.1158/1078-0432.CCR-15-0528] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
119 Heinzow HS, Meister T, Nass D, Köhler M, Spieker T, Wolters H, Domschke W, Domagk D. Outcome of supraselective transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol 2011;46:201-10. [PMID: 20969491 DOI: 10.3109/00365521.2010.525256] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
120 Lei JY, Wang WT, Yan LN. “Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China. World J Gastroenterol. 2013;19:8093-8098. [PMID: 24307805 DOI: 10.3748/wjg.v19.i44.8093] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
121 Wang LY, Zheng SS. Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation. J Zhejiang Univ Sci B 2018;19:497-504. [PMID: 29971988 DOI: 10.1631/jzus.B1700156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
122 Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol. 2012;138:153-161. [PMID: 22071603 DOI: 10.1007/s00432-011-] [Reference Citation Analysis]
123 Bai DS, Dai Z, Zhou J, Liu YK, Qiu SJ, Tan CJ, Shi YH, Huang C, Wang Z, He YF. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology. 2009;49:460-470. [PMID: 19053044 DOI: 10.1002/hep.22638] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 5.3] [Reference Citation Analysis]
124 Zhou L, Rui JA, Ye DX, Wang SB, Chen SG, Qu Q. Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection. World J Surg. 2008;32:1748-1756. [PMID: 18493820 DOI: 10.1007/s00268-008-9615-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 4.8] [Reference Citation Analysis]
125 Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 2009;15:1843-1851. [PMID: 19938117 DOI: 10.1002/lt.21943] [Cited by in Crossref: 80] [Cited by in F6Publishing: 59] [Article Influence: 7.3] [Reference Citation Analysis]
126 Menyhárt O, Nagy Á, Győrffy B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 2018;5:181006. [PMID: 30662724 DOI: 10.1098/rsos.181006] [Cited by in Crossref: 124] [Cited by in F6Publishing: 122] [Article Influence: 41.3] [Reference Citation Analysis]
127 Ismail H, Broniszczak D, Kaliciński P, Markiewicz-Kijewska M, Teisseyre J, Stefanowicz M, Szymczak M, Dembowska-Bagińska B, Kluge P, Perek D, Kościesza A, Dzik E, Lembas A, Teisserye M. Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant 2009;13:682-92. [PMID: 19496985 DOI: 10.1111/j.1399-3046.2009.01062.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
128 Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004;127:S277-S282. [PMID: 15508095 DOI: 10.1007/978-1-60327-376-3_19] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
129 Kuo W, Hsia C, Loong C, Liu C, Tsai H, Tseng H, Lee R, Tsou M, Wu C, Lui W. Outcome of foreign residents undergoing deceased donor liver transplantation in China: A single-center experience in Taiwan: Foreign Residents Undergoing Liver Transplantation in China. Liver Transpl 2009;15:1579-85. [DOI: 10.1002/lt.21859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
130 Imai K, Beppu T, Nakayama Y, Ishiko T, Horino K, Komori H, Masuda T, Hayashi H, Okabe H, Baba Y, Watanabe M, Takamori H, Awai K, Yamashita Y, Baba H. Preoperative prediction of poorly differentiated components in small-sized hepatocellular carcinoma for safe local ablation therapy. J Surg Oncol 2009;100:121-6. [PMID: 19402077 DOI: 10.1002/jso.21302] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
131 Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok A; NIH HBV OLT Study Group. Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant 2011;25:E152-62. [PMID: 21077950 DOI: 10.1111/j.1399-0012.2010.01349.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
132 Iguchi T, Shirabe K, Aishima S, Wang H, Fujita N, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T. New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma: Predicting Prognosis After Living-donor Liver Transplantation. Transplantation. 2015;99:1236-1242. [PMID: 25427164 DOI: 10.1097/tp.0000000000000489] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 8.2] [Reference Citation Analysis]
133 Zhao J, Mao J, Li W. Association of Tumor Grade With Long-Term Survival in Patients With Hepatocellular Carcinoma After Liver Transplantation. Transplantation Proceedings 2019;51:813-9. [DOI: 10.1016/j.transproceed.2018.12.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
134 Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg. 2007;246:502-509; discussion 509. [PMID: 17717454 DOI: 10.1097/sla.0b013e318148c704] [Cited by in Crossref: 331] [Cited by in F6Publishing: 99] [Article Influence: 23.6] [Reference Citation Analysis]
135 Li C, Chen R, Lii J, Chen W, Shih L, Zhang T, Tu H. Magnetic Resonance Imaging Appearance of Well-differentiated Hepatocellular Carcinoma: . Journal of Computer Assisted Tomography 2006;30:597-603. [DOI: 10.1097/00004728-200607000-00008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
136 Beckebaum S, Sotiropoulos GC, Klein CG, Broelsch CE, Saner F, Paul A, Gerken G, Cicinnati VR. Predictive Factors of Outcome in Patients Transplanted for Hepatitis B. Transplantation 2009;87:872-81. [DOI: 10.1097/tp.0b013e31819a6697] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
137 Kee KM, Wang JH, Lin CY, Wang CC, Cheng YF, Lu SN. Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. Dig Dis Sci. 2013;58:2721-2728. [PMID: 23703450 DOI: 10.1007/s10620-013-2716-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
138 Schraiber LDS, de Mattos AA, Zanotelli ML, Cantisani GPC, Brandão ABM, Marroni CA, Kiss G, Ernani L, Marcon PDS. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma. Medicine (Baltimore) 2016;95:e2478. [PMID: 26817881 DOI: 10.1097/MD.0000000000002478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
139 Sotiropoulos GC, Lang H, Nadalin S, Neuhäuser M, Molmenti EP, Baba HA, Paul A, Saner FH, Weber F, Hilgard P, Frilling A, Broelsch CE, Malagó M. Liver Transplantation for Hepatocellular Carcinoma: University Hospital Essen Experience and Metaanalysis of Prognostic Factors. Journal of the American College of Surgeons 2007;205:661-75. [DOI: 10.1016/j.jamcollsurg.2007.05.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
140 Wong SN, Reddy KR, Keeffe EB, Han SH, Gaglio PJ, Perrillo RP, Tran TT, Pruett TL, Lok AS. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl. 2007;13:334-342. [PMID: 17154401 DOI: 10.1002/lt.20959] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
141 Pommergaard HC, Rostved AA, Adam R, Thygesen LC, Salizzoni M, Gómez Bravo MA, Cherqui D, Filipponi F, Boudjema K, Mazzaferro V, Soubrane O, García-Valdecasas JC, Prous JF, Pinna AD, O'Grady J, Karam V, Duvoux C, Rasmussen A; European Liver and Intestine Transplant Association (ELITA). Vascular invasion and survival after liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. HPB (Oxford) 2018;20:768-75. [PMID: 29622402 DOI: 10.1016/j.hpb.2018.03.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
142 van Malenstein H, Komuta M, Verslype C, Vandecaveye V, Van Calster B, Topal B, Laleman W, Cassiman D, Van Steenbergen W, Aerts R. Histology obtained by needle biopsy gives additional information on the prognosis of hepatocellular carcinoma. Hepatol Res. 2012;42:990-998. [PMID: 22548688 DOI: 10.1111/j.1872-034x.2012.01010.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
143 Cauchy F, Fuks D, Belghiti J. HCC: current surgical treatment concepts. Langenbecks Arch Surg 2012;397:681-95. [DOI: 10.1007/s00423-012-0911-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
144 Diniz PHC, Silva SDDC, Faria LC, Vidigal PVT, Ferrari TCA. Clinical and laboratory parameters as predictors of long-term outcome according to the etiology of underlying chronic liver disease in patients who underwent liver transplantation for hepatocellular carcinoma treatment. Clinics (Sao Paulo) 2020;75:e1529. [PMID: 32520221 DOI: 10.6061/clinics/2020/e1529] [Reference Citation Analysis]
145 Liu F, Wei Y, Wang W, Chen K, Yan L, Wen T, Zhao J, Xu M, Li B. Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection. PLoS One. 2012;7:e48932. [PMID: 23145027 DOI: 10.1371/journal.pone.0048932] [Cited by in Crossref: 26] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
146 Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, Weiss M, Wolfgang CL, Choti MA, Pawlik TM. Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol 2014;21:147-54. [PMID: 23959056 DOI: 10.1245/s10434-013-3211-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
147 Dharancy S, Boitard J, Decaens T, Sergent G, Boleslawski E, Duvoux C, Vanlemmens C, Meyer C, Gugenheim J, Durand F. Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study. Liver Transpl. 2007;13:665-671. [PMID: 17427172 DOI: 10.1002/lt.21109] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
148 Gordon-Weeks AN, Snaith A, Petrinic T, Friend PJ, Burls A, Silva MA. Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria. Br J Surg. 2011;98:1201-1208. [PMID: 21618496 DOI: 10.1002/bjs.7561] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
149 Fujiki M, Aucejo F, Kim R. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this? Clin Transplant 2013;27:169-77. [PMID: 23216662 DOI: 10.1111/ctr.12042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
150 de Villa V, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist. 2007;12:1321-1331. [PMID: 18055852 DOI: 10.1634/theoncologist.12-11-1321] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 6.2] [Reference Citation Analysis]
151 Xu X, Ke QH, Shao ZX, Wu J, Chen J, Zhou L, Zheng SS. The value of serum alpha-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci. 2009;54:385-388. [PMID: 18563566 DOI: 10.1007/s10620-008-0349-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
152 Simoneau E, Hassanain M, Madkhali A, Salman A, Nudo CG, Chaudhury P, Metrakos P. (18)F-Fluorodeoxyglucose positron-emission tomography could have a prognostic role in patients with advanced hepatocellular carcinoma. Curr Oncol. 2014;21:e551-e556. [PMID: 25089106 DOI: 10.3747/co.21.1959] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
153 Jarnagin WR. Management of small hepatocellular carcinoma: a review of transplantation, resection, and ablation. Ann Surg Oncol. 2010;17:1226-1233. [PMID: 20405327 DOI: 10.1245/s10434-010-0978-3] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
154 Wu TH, Yu MC, Chen TC, Lee CF, Chan KM, Wu TJ, Chou HS, Lee WC, Chen MF. Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma. J Surg Oncol. 2012;105:85-90. [PMID: 22161900 DOI: 10.1002/jso.22060] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
155 Han YS, Choi DL, Park JB. Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation--eighteen months of follow-up: a case report. Transplant Proc. 2008;40:2835-2836. [PMID: 18929876 DOI: 10.1016/j.transproceed.2008.07.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
156 Li X, Huang L, Leng X. Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation. J Cancer Res Clin Oncol 2018;144:2465-74. [PMID: 30259149 DOI: 10.1007/s00432-018-2756-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
157 Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg 2012;16:874-81. [PMID: 21975686 DOI: 10.1007/s11605-011-1710-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
158 Huda A, Newcomer R, Harrington C, Blegen MG, Keeffe EB. High rate of unemployment after liver transplantation: analysis of the United Network for Organ Sharing database. Liver Transpl. 2012;18:89-99. [PMID: 21837745 DOI: 10.1002/lt.22408] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
159 Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007;120:2650-2655. [PMID: 17304512 DOI: 10.1002/ijc.22616] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 5.3] [Reference Citation Analysis]
160 DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg. 2011;253:166-172. [PMID: 21294289 DOI: 10.1097/sla.0b013e31820508f1] [Cited by in Crossref: 170] [Cited by in F6Publishing: 89] [Article Influence: 17.0] [Reference Citation Analysis]
161 Welker MW, Bechstein WO, Zeuzem S, Trojan J. Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge. Transpl Int. 2013;26:109-118. [PMID: 22994652 DOI: 10.1111/j.1432-2277.2012.01562.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 10.0] [Reference Citation Analysis]
162 Gringeri E, Boetto R, Bassi D, D’Amico FE, Polacco M, Romano M, Neri D, Feltracco P, Zanus G, Cillo U. Laparoscopic microwave thermal ablation for late recurrence of local hepatocellular carcinoma after liver transplant: case report. Prog Transplant. 2014;24:142-145. [PMID: 24919730 DOI: 10.7182/pit2014632] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]